Skip to main content

Table 4 Multivariable risk factors for early parasitaemia positivity rates in Africa

From: Early parasitological response following artemisinin-containing regimens: a critical review of the literature

 

Day 1

Day 2

Day 3

Variable

AOR (95% CI)

P-value

AOR (95% CI)

P-value

AOR (95% CI)

P-value

Age

0.99 (0.97-1.02)

0.689

1.02 (0.98-1.06)

0.368

1.04 (0.97-1.12)

0.252

Log e parasitaemia

1.76 (1.18-2.62)

0.005

1.59 (1.16-2.18)

0.004

3.01 (1.18-7.64)

0.021

Year

0.84 (0.73-0.96)

0.012

0.92 (0.79-1.07)

0.270

0.78 (0.62-0.97)

0.026

Treatment

      

DHA+PIP

1.00

 

1.00

 

1.00

 

AL

1.32 (1.02-1.71)

0.033

1.61 (1.14-2.28)

0.007

5.03 (0.58 – 43.52)

0.143

AS+MQ

1.22 (0.77-1.91)

0.398

2.04 (0.84-4.94)

0.115

9.45(0.61-146.06.76)

0.108

AS+SP

0.74 (0.32-1.74)

0.495

1.91 (1.16-3.14)

0.011

4.89 (0.50-47.34)

0.171

AS+AQ

1.06 (0.76-1.46)

0.740

1.84 (1.23-2.74)

0.003

4.98 (0.59-42.07)

0.141

AS alone

0.55(0.12-2.50)

0.439

0.74 (0.28-1.97)

0.548

ND

 
  1. Only patients who received artemisinin derivative until Day 1 (2 or 3) are included for analysis of PPRday1 (2 or 3). Study arms with rectal artesunate are excluded. Positivity rate equal to 0% on Day 2 was carried forward to Day 3 if Day 3 rate was not reported.
  2. ND= There were no patient data available or patients with detectable parasitaemia in this category so the OR could not be estimated. For the purpose of logistic model this treatment group was merged with all other treatments (not included in the listed categories).